Is ADAPY or VICI a better dividend investment in 2026?

ADAPY currently yields 17391.30% with a 5% 5-year dividend growth rate. VICI yields 6.57% with 8.1% growth. The better choice depends on your goal: ADAPY offers higher current income.

What is the dividend yield difference between ADAPY and VICI?

ADAPY has a forward dividend yield of 17391.30% ($2.00/share annually). VICI yields 6.57% ($1.78/share annually). The yield gap is 17384.73 percentage points.

Home › Compare › ADAPY vs VICI

ADAPY vs VICI: Dividend Comparison 2026

ADAPY yields 17391.30% · VICI yields 6.57%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ADAPY wins by $13116176655014998016.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ADAPY

● Live price

17391.30%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$13116176655014998016.00M

Annual income

$12,969,477,336,575,606,000,000,000.00

Full ADAPY calculator →

VICI

VICI Properties Inc.

● Live price

6.57%

Share price

$27.12

Annual div

$1.78

5Y div CAGR

44.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$988.8K

Annual income

$623,261.32

Full VICI calculator →

Portfolio growth — ADAPY vs VICI

📍 ADAPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ADAPY	VICI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ADAPY + VICI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ADAPY pays

VICI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADAPY

Annual income on $10K today (after 15% tax)

$1,478,260.87/yr

After 10yr DRIP, annual income (after tax)

$11,024,055,736,089,265,000,000,000.00/yr

VICI

Annual income on $10K today (after 15% tax)

$558.67/yr

After 10yr DRIP, annual income (after tax)

$529,772.12/yr

At 15% tax rate, ADAPY beats the other by $11,024,055,736,089,265,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADAPY + VICI for your $10,000?

ADAPY: 50%VICI: 50%

100% VICI50/50100% ADAPY

Portfolio after 10yr

$6558088327507499008.00M

Annual income

$6,484,738,668,287,803,000,000,000.00/yr

Blended yield

98.88%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ADAPY

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$2.83

+24508.7% upside vs current

Range: $1.00 — $4.00

Altman Z

-15.9

Piotroski

0/9

VICI

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$31.60

+16.5% upside vs current

Range: $30.00 — $33.00

Altman Z

1.4

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADAPY buys

VICI buys

No recent congressional trades found for ADAPY or VICI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricADAPYVICI

Forward yield	17391.30% ✓	6.57%
Annual dividend / share	$2.00 ✓	$1.78
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	44.3% ✓
Portfolio after 10y	$13116176655014998016.00M ✓	$988.8K
Annual income after 10y	$12,969,477,336,575,606,000,000,000.00 ✓	$623,261.32
Total dividends collected	$13106484814212466688.00M ✓	$948.4K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Buy
Analyst price target	$2.83	$31.60 ✓

Year-by-year: ADAPY vs VICI ($10,000, DRIP)

Year	ADAPY Portfolio	ADAPY Income/yr	VICI Portfolio	VICI Income/yr	Gap
1← crossover	$1,749,830	$1,739,130.43	$11,368	$948.43	+$1.74M → ADAPY
2	$286,281,979	$284,409,660.27	$13,339	$1,493.16	+$286.27M → ADAPY
3	$43,793,237,807	$43,486,916,089.97	$16,326	$2,426.21	+$43793.22M → ADAPY
4	$6,263,959,119,982	$6,217,100,355,528.48	$21,123	$4,112.15	+$6263959.10M → ADAPY
5	$837,788,422,535,934	$831,085,986,277,552.80	$29,379	$7,368.23	+$837788422.51M → ADAPY
6	$104,780,184,325,077,740	$103,883,750,712,964,290.00	$44,804	$14,191.64	+$104780184325.03M → ADAPY
7	$12,254,629,759,849,812,000	$12,142,514,962,621,979,000.00	$76,658	$29,972.12	+$12254629759849.74M → ADAPY
8	$1,340,341,587,727,856,400,000	$1,327,229,133,884,817,100,000.00	$150,894	$71,015.81	+$1340341587727856.25M → ADAPY
9	$137,102,166,765,785,570,000,000	$135,668,001,266,916,780,000,000.00	$350,814	$193,582.47	+$137102166765785568.00M → ADAPY
10	$13,116,176,655,014,997,000,000,000	$12,969,477,336,575,606,000,000,000.00	$988,809	$623,261.32	+$13116176655014998016.00M → ADAPY

ADAPY vs VICI: Complete Analysis 2026

ADAPY — Stock

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full ADAPY Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →

📬

Get this ADAPY vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADAPY vs SCHD ADAPY vs JEPI ADAPY vs O ADAPY vs KO ADAPY vs MAIN ADAPY vs NNN ADAPY vs EPRT ADAPY vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.